Diplomat Pharmacy to Distribute Recently Approved PARP Inhibitor Zejula in the US

Diplomat Pharmacy to Distribute Recently Approved PARP Inhibitor Zejula in the US
Diplomat Pharmacy will be one of the companies distributing Zejula (niraparib), a recently approved treatment for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in the United States. Zejula is an oral, once-daily inhibitor of the proteins poly(ADP-ribose) polymerase (PARP) 1 and 2. It is the first of its class to receive approval

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *